<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-04344R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0002743</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology</subject><subject>Cell Biology/Cellular Death and Stress Responses</subject><subject>Cell Biology/Gene Expression</subject><subject>Genetics and Genomics/Gene Function</subject><subject>Molecular Biology/Transcription Initiation and Activation</subject></subj-group></article-categories><title-group><article-title>Splice Variants of the Forkhead Box Protein AFX Exhibit Dominant Negative Activity and Inhibit AFX&#x003b1;-Mediated Tumor Cell Apoptosis</article-title><alt-title alt-title-type="running-head">AFX Variants in Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Eun Jig</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jeong Mo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Mi Kyung</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jameson</surname><given-names>J. Larry</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Endocrinology, Yonsei University College of Medicine, Seoul, Korea</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Pathology, National Health Insurance Corporation, Ilsan Hospital, Koyang, Korea</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Fugmann</surname><given-names>Sebastian D.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">National Institute on Aging, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>ljameson@northwestern.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: EJL. Performed the experiments: EJL JMK MKL. Analyzed the data: EJL. Contributed reagents/materials/analysis tools: EJL JLJ. Wrote the paper: EJL JLJ.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>7</month><year>2008</year></pub-date><volume>3</volume><issue>7</issue><elocation-id>e2743</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2008</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2008</year></date></history><copyright-statement>Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Loss-of-function in the apoptosis-inducing genes is known to facilitate tumorigenesis. AFX (FOXO4), a member of forkhead transcription factors functions as a tumor suppressor and has 2 isoforms, AFX&#x003b1; (505 a.a.) and AFX&#x003b6; (450 a.a.). In human cancer cells, we identified an N-terminally deleted form of AFX&#x003b1; (&#x003b1;198-505), translated from a downstream start and 2 short N-terminal AFX proteins (90, and 101 a.a.) produced by aberrant splicing.</p></sec><sec><title>Methods and Findings</title><p>We investigated the expression and role of these AFX variants. Cell transduction study revealed that short N-terminal AFX proteins were not stable. Though &#x003b1;(198-505) protein expression was detected in the cytoplasm and nucleus, &#x003b1;(198-505) expressing cells did not show a nucleocytoplasmic shuttling mediated by PI3 kinase signaling. Whereas, we observed this shuttling in cells expressing either AFX&#x003b1; or AFX&#x003b6; protein. AFX&#x003b6; and &#x003b1;(198-505) lost the ability to transactivate BCL6 or suppress cyclin D2 gene expression. These variants did not induce cancer cell death whereas AFX&#x003b1; resulted in apoptosis. We found that AFX&#x003b6; and &#x003b1;(198-505) suppress the AFX&#x003b1; stimulation of BCL6 promoter in a dose dependent manner, indicating dominant negative activity. These variants also inhibited AFX&#x003b1; induction of apoptosis.</p></sec><sec><title>Conclusions</title><p>Loss of function by aberrant splicing and the dominant negative activity of AFX variants may provide a mechanism for enhanced survival of neoplastic cells.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>AFX (FOXO4) is a member of the class O (FOXO) subfamily of forkhead transcription factors that includes the functionally related proteins FOXO1 (FKHR), FOXO3a (FKHRL1), and FOXO4 <xref ref-type="bibr" rid="pone.0002743-Arden1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Accili1">&#x0005b;2&#x0005d;</xref>. FOXO transcription factors have important roles in metabolism, cellular proliferation, and apoptosis. Overproduction of FOXOs induces either cell cycle arrest or apoptosis. When relieved of FOXO activity, cells re-enter the cell cycle and start to proliferate <xref ref-type="bibr" rid="pone.0002743-Burgering1">&#x0005b;3&#x0005d;</xref>. A role for FOXO members in tumorigenesis was initially suggested by the observation that FOXO members are involved chromosomal translocations in certain types of tumors <xref ref-type="bibr" rid="pone.0002743-Barr1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-So1">&#x0005b;5&#x0005d;</xref>. The PAX3-FKHR fusion product has been shown to transform cells in culture <xref ref-type="bibr" rid="pone.0002743-Scheidler1">&#x0005b;6&#x0005d;</xref>. However, translocations involving FOXO proteins might also result in loss-of-function of a FOXO allele.</p><p>AFX is known to have two isoforms, AFX&#x003b1; (505 amino acids) and AFX&#x003b6; (450 amino acids) <xref ref-type="bibr" rid="pone.0002743-Yang1">&#x0005b;7&#x0005d;</xref>. AFX&#x003b6; is a splice variant that encodes a shorter protein lacking amino acids 58-112, including the first 16 amino acids of the forkhead domain. AFX&#x003b1; is ubiquitously expressed, whereas AFX&#x003b6; is expressed predominantly in liver, kidney, pancreas, heart, and placenta. AFX&#x003b6; transcripts are not detected in ovary, testis, brain, prostate, colon, and leukocyte. The different tissue distributions AFX&#x003b1; and AFX&#x003b6; suggest distinct transcriptional regulation and actions on a different subset of target genes.</p><p>In this report, we describe novel spliced forms of the AFX transcript in human cancer cells and their effect on tumor apoptosis and growth.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>AFX splicing variants</title><p>PCR amplification of reverse-transcribed cDNA samples from human cancer cell lines was performed using a primer set that anneals to both AFX&#x003b1; and AFX&#x003b6; cDNAs. The upper band (445 bp) corresponds to AFX&#x003b1; and lower band (290 bp) contains AFX&#x003b6;. There was a slight difference in the size of AFX&#x003b6; bands among the cell lines, prompting us to consider possible splicing variants (<xref ref-type="fig" rid="pone-0002743-g001">Fig. 1A</xref>). Direct sequencing of lower bands identified the AFX&#x003b6; isoform, as well as overlapping and mixed sequences near splice acceptor site of AFX&#x003b6; isoform (not shown). The lower bands were cloned and sequenced to investigate these sequences further. Two novel splicing variants were identified, in which the splice acceptance occurred aberrantly at 4 and 14 bases before splice acceptor site of the AFX&#x003b6; isoform (<xref ref-type="fig" rid="pone-0002743-g001">Fig. 1B, C</xref>). This aberrant splicing results in either a 4 or 14 base insertion, leading to a shift of the reading frame and producing premature stop codon. Splicing variants with the 4 or 14 base insertion encode predicted proteins of 90 (AFXtr1) or 101 (AFXtr2) amino acids, respectively (<xref ref-type="fig" rid="pone-0002743-g001">Fig. 1C</xref>). A variety of tumor cells showed different patterns of AFX transcripts (<xref ref-type="fig" rid="pone-0002743-g001">Fig. 1A</xref>). Either AFXtr1 or AFXtr2 were detected in most tumor cells. AFX&#x003b6; was detected in DOV13, OVCA429, CaCO2, HEK293, and 293FT cells. AFX&#x003b1; expression was absent in OVCA429 and 293FT cells. JEG3 cells express only AFX&#x003b1;. Percent ratio of AFX&#x003b6;, AFXtr1, and AFXtr2 was different each other according to tumor cells (<xref ref-type="fig" rid="pone-0002743-g001">Fig. 1A</xref>).</p><fig id="pone-0002743-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002743.g001</object-id><label>Figure 1</label><caption><title>AFX splicing variants.</title><p>(A) RT-PCR of total RNA samples from human cancer cell lines. The upper band (445 bp) represents AFX&#x003b1; and the lower band (290 bp) contains AFX&#x003b6;. Lower bands were cloned and sequenced. Percent ratio of AFX&#x003b6;, AFXtr1, and AFXtr2 was calculated. 1-12, Sequencing results of cloned lower bands from each cell line (&#x003b1;, AFX&#x003b1;; &#x003b6;, AFX&#x003b6;; tr1, AFXtr1; and tr2, AFXtr2); 13, AFX&#x003b1; cDNA; and 14, AFX&#x003b6; cDNA. (B, C) Schematic representation of AFX&#x003b1; and AFX&#x003b6;, and AFX splicing variants by aberrant splicing. The splice acceptance occurred aberrantly at 4 (b) and 14 (c) bases before splice acceptor site (a) of AFX&#x003b6; isoform. This aberrant splicing results in 4 and 14 base insertions, leading to a shift of reading frame and producing premature stop codon. Splicing variants with 4 and 14 bases insertion have 90 (AFXtr1) and 101 (AFXtr2) amino acids (a.a.), respectively.</p></caption><graphic xlink:href="pone.0002743.g001"/></fig><p>We became interested in the N-terminally truncated AFX&#x003b1; proteins because AFXtr1 and AFXtr2 are prematurely terminated in exon 1, and three potential alternative start codons (M1, M2, and M3) are present in exon 1b and 2 (<xref ref-type="fig" rid="pone-0002743-g002">Fig. 2A</xref>). M3 is the methionine codon located at the end of forkhead domain. It contains a consensus Kozak sequence for initiation of translation and thus potentially encodes an N-terminally deleted AFX&#x003b1;. Western blot analyses using an anti-HA antibody from the lysate of 293FT cells transfected with C-terminal hemaglutinin (HA) epitope-tagged AFX&#x003b1; detected an additional band, suggesting a presence of N-terminally deleted AFX protein (<xref ref-type="fig" rid="pone-0002743-g002">Fig. 2B</xref>, arrow). In order to identify this product, we generated three N-terminally deleted AFX constructs tagged with C-terminal-HA epitope {&#x003b1;(131-505)-HA, &#x003b1;(178-505)-HA, and &#x003b1;(198-505)-HA}. Western blotting with anti-AFX antibody (C-terminal specific) after immunoprecipitation with anti-HA antibody of transfected cell lysates confirmed the presence of the &#x003b1;(198-505) protein (<xref ref-type="fig" rid="pone-0002743-g002">Fig. 2C</xref>, arrow).</p><fig id="pone-0002743-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002743.g002</object-id><label>Figure 2</label><caption><title>Identification of N-terminally deleted AFX protein, &#x003b1;(198-505).</title><p>(A) Three start codons (M1, M2, and M3) are present in exon 1b and 2. M3 is the methionine codon located at the end of forkhead domain, which contains a consensus Kozak sequence for initiation of translation. (B) Western blot analysis. We detected an additional band (arrow) using anti-HA antibody from the lysate of 293-FT cells transfected with AFX&#x003b1;-HA (C-terminal tagged), suggesting a presence of N-terminally deleted AFX protein. (C) Immunoprecipitation analysis. To identify truncated protein, three N-terminally deleted AFX constructs tagged with C-terminal-HA epitope {&#x003b1;(131-505)HA, &#x003b1;(178-505)HA, and &#x003b1;(198-505)HA} were transfected. Western blotting with anti-AFX antibody (C-terminal specific) after immunoprecipitation with anti-HA antibody of transfected cell lysates revealed &#x003b1;(198-505) protein (arrow).</p></caption><graphic xlink:href="pone.0002743.g002"/></fig></sec><sec id="s2b"><title>Expression and subcellular localization of AFX variants</title><p>Cellular protein processing and localization of AFX variants was examined by immunofluorescence (IF) staining. JEG3 cells were transfected with the constructs carrying the N- or C-terminal HA epitope in-frame with AFX&#x003b1;-HA, AFX&#x003b6;-HA, or &#x003b1;(198-505)-HA. Immunofluorescence positivity was detected in about 5&#x02013;8&#x00025; of JEG3 cells. No protein expression was detected in cells transfected with HA-AFXtr1 and HA-AFXtr2 (Data not shown). To achieve high levels of gene expression, we generated adenoviral vectors carrying these constructs. After determining the dose of adenoviral vectors required to achieve 95&#x02013;100&#x00025; expression of the control &#x003b2;-galactosidase gene in HeLa cells, protein expression was still not detected for vectors containing HA-AFXtr1 or HA-AFXtr2 (data not shown), whereas 90&#x02013;95&#x00025; of cells expressed AFX&#x003b1;-HA, AFX&#x003b6;-HA, or &#x003b1;(198-505)-HA in either cytoplasms and nuclei (<xref ref-type="fig" rid="pone-0002743-g003">Fig. 3A</xref>). These results indicate that the short aminoterminal-AFX proteins are not appropriately processed or stable in the cells, although the product from the alternate translation start site &#x003b1;(198-505) is produced.</p><fig id="pone-0002743-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002743.g003</object-id><label>Figure 3</label><caption><title>Expression and subcellular localization of AFX variants.</title><p>HeLa cells were seeded on fibronectin coated cover glass and infected with adenoviral vectors carrying C-terminal HA-epitope tagged AFXs. Immunofluorescence staining using anti-HA antibody was performed. (A) Not treated. (B) Treated with insulin, EGF, LY294002, and LY294002 followed by EGF. &#x003b1;, AFX&#x003b1;; and &#x003b6;, AFX&#x003b6;.</p></caption><graphic xlink:href="pone.0002743.g003"/></fig><p>The effect of the cell signaling on subcellular localization was assessed by adding insulin, EGF, or LY294002 (a PI3 kinase inhibitor). Insulin and EGF treatment induced the excursions of AFX&#x003b1; and AFX&#x003b6; to cytoplasms and LY294002 pretreatment prevented these excursions, indicating that nucleocytoplasmic shuttling of AFX&#x003b1; or AFX&#x003b6; protein is occurred and regulated by PI3 kinase signaling pathway. Whereas &#x003b1;(198-505) expressing cells did not show this shuttling (<xref ref-type="fig" rid="pone-0002743-g003">Fig. 3B</xref>). This defect may be due to the fact that &#x003b1;(198-505) has lost two binding sites for 14-3-3 protein and half of the nuclear localization sequence (182-211 amino acids) <xref ref-type="bibr" rid="pone.0002743-VanDerHeide1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Obsilova1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Matsuzaki1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Boura1">&#x0005b;11&#x0005d;</xref>.</p></sec><sec id="s2c"><title>AFX variants fail to transactivate the BCL6 gene or suppress the cyclin D2 gene</title><p>The transcriptional activity of AFX&#x003b6; and &#x003b1;(198-505) was compared to AFX&#x003b1; using a luciferase reporter system. The amounts of plasmid vectors transfected were carefully optimized to minimize nonspecific effects <xref ref-type="bibr" rid="pone.0002743-Ishikawa1">&#x0005b;12&#x0005d;</xref> and luciferase values were normalized by protein measurements. AFX&#x003b6; and &#x003b1;(198-505) did not stimulate 3IRS-TATA-Luc, whereas AFX&#x003b1; activated this reporter about 15-fold (<xref ref-type="fig" rid="pone-0002743-g004">Fig. 4A</xref>). Two representative target genes, BCL6 and cyclin D2, were also examined. BCL6 is a transcriptional repressor of BCL-X<sub>L</sub>, an antiapoptotic protein, and the AFX protein is thought to induce activates apoptosis by stimulation of BCL6 <xref ref-type="bibr" rid="pone.0002743-Tang1">&#x0005b;13&#x0005d;</xref>. The cell cycle inhibition by AFX protein involves down-regulation of cyclin D <xref ref-type="bibr" rid="pone.0002743-Schmidt1">&#x0005b;14&#x0005d;</xref>. In 293FT cells, AFX&#x003b6; and &#x003b1;(198-505) did not stimulate BCL6p-Luc or suppress CD2p-Luc, whereas AFX&#x003b1; stimulated BCL6p-Luc 13-fold and suppressed CD2p-Luc by 75&#x00025; (<xref ref-type="fig" rid="pone-0002743-g004">Fig. 4B, C</xref>). RT-PCR and Western blot analyses were used to investigate the effect of the AFX variants on the expression of BCL6 or cyclin D2 in cells infected with adenoviral vectors carrying AFX&#x003b1;, AFX&#x003b6;, or &#x003b1;(198-505). Whereas AFX&#x003b1; induced BCL6 expression in MCF7 cells, Ad-&#x003b6; or Ad-&#x003b1;(198-505) did not increase either BCL6 mRNA or protein (<xref ref-type="fig" rid="pone-0002743-g004">Fig. 4D</xref>). Ad-&#x003b1; suppressed cyclin D2 expression, however Ad-&#x003b6; or Ad-&#x003b1;(198-505) lost the ability to suppress its expression in MCF7 or OVCA429 cells (<xref ref-type="fig" rid="pone-0002743-g004">Fig. 4E</xref>). These results indicate that the AFX variants are loss-of-function mutants.</p><fig id="pone-0002743-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002743.g004</object-id><label>Figure 4</label><caption><title>AFX variants do not transactivate the BCL6 gene or suppress the cyclin D2 gene.</title><p>(A, B, C) Transcriptional activity of AFX&#x003b6; and &#x003b1;(198-505) compared to AFX&#x003b1; using a luciferase reporter system. 293-FT cells were co-transfected with AFX expression vectors and luciferase reporter constructs, 3IRS-TATA-Luc (A); BCL6p-Luc (B); and CD2p-Luc (C). Luciferase values were normalized by protein measurements. Results were averaged from 3 independent experiments and are plotted as means&#x000b1;standard deviations for quadruplicated wells. (D) RT-PCR and Western blot analysis of BCL6 expression in MCF7 cells infected with Ad-E, Ad-&#x003b1;, Ad-&#x003b6; or Ad-&#x003b1;(198-505). (E). Western blot analysis of cyclin D2 expression in MCF7 and OVCA429 cells infected with Ad-E, Ad-&#x003b1;, Ad-&#x003b6; or Ad-&#x003b1;(198-505).</p></caption><graphic xlink:href="pone.0002743.g004"/></fig></sec><sec id="s2d"><title>AFX variants have lost the ability to suppress tumor cell growth</title><p>HepG2, T47D, HeLa, OVCA429, and OVCA420 cells were infected with adenoviral vectors (from 2.5 to 10 PFU/cell ) expressing AFX&#x003b1;, AFX&#x003b6;, or &#x003b1;(198-505). Cell viability was assessed using the MTS assay at day 6 and the percent cell survival was calculated compared to Ad-Empty (Ad-E) infection. Infection of Ad-&#x003b1; suppressed 70&#x02013;95&#x00025; cell growth, whereas Ad-&#x003b6; or Ad-&#x003b1;(198-505) did not suppress cell growth (<xref ref-type="fig" rid="pone-0002743-g005">Fig. 5A</xref>), indicating that the AFX variants have lost the ability to suppress tumor cell growth.</p><fig id="pone-0002743-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002743.g005</object-id><label>Figure 5</label><caption><title>AFX variants do not suppress tumor cell growth.</title><p>(A) Cell survival after transduction of AFX&#x003b1;, AFX&#x003b6;, and &#x003b1;(198-505). HepG2, T47D, HeLa, OVCA429, and OVCA420 cells were infected with adenoviral vectors from 2.5 to 10 PFU/cell and cell viability was assessed using the MTS assay at day 6. The amount of adenoviral vectors for each cell line was optimized to achieve 95&#x02013;100&#x00025; expression levels. Percent cell survival was calculated compared to Ad-E infection. (B) AFX&#x003b6; and &#x003b1;(198-505) inhibits AFX&#x003b1; induced growth suppression. We used an adenoviral vector {Ad-&#x003b1;(1-200)} containing AFX&#x003b1;(1-200), a C-terminal truncation mutant that has dominant negative activity. Four days after co-infection of adenoviral vectors, cell viability was assayed. Results were averaged from 3 independent experiments and are plotted as means&#x000b1;standard deviations for quadruplicated wells. (C) Prevention of Ad-&#x003b1; induced apoptosis by Ad-&#x003b6; and Ad-&#x003b1;(198-505). Double immunofluorescent staining was performed to identify cells infected with two viruses. HeLa cells infected with Ad-&#x003b1; showed apoptotic nuclei (arrow), whereas HeLa cells co-infected with either Ad-&#x003b6; or Ad-&#x003b1;(198-505) did not show apoptosis. Anti-AFX(N), N-terminal specific antibody against AFX; E, Ad-E, &#x003b1;; Ad-&#x003b1;; &#x003b6;, Ad-&#x003b6; ; &#x003b6;-HA, Ad-&#x003b6;-HA; and &#x003b1;(198-505), Ad-&#x003b1;(198-505).</p></caption><graphic xlink:href="pone.0002743.g005"/></fig></sec><sec id="s2e"><title>AFX variants inhibited AFX&#x003b1; induction of cell death by a dominant negative effect on the BCL6 gene</title><p>We examined whether AFX variants might inhibit AFX&#x003b1; induction of apoptosis through dominant negative activity. An additional adenoviral vector {Ad-&#x003b1;(1-200)} were constructed containing AFX&#x003b1;(1-200), a C-terminal truncation mutant that contains a functional DNA-binding domain, but lacks a transactivation domain. A similar FOXO1(1-255) construct has been shown to have dominant negative activity <xref ref-type="bibr" rid="pone.0002743-Nakae1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Nakae2">&#x0005b;16&#x0005d;</xref>. Ad-&#x003b1;(1-200) infection alone did not induce cell death in HepG2, T47D, HeLa, OVCA429, and OVCA420 cells (data not shown). Co-infection of Ad-&#x003b1; with equal (5 PFU/cell) or higher (15 PFU/cell) amounts of Ad-E, Ad-&#x003b6;, Ad-&#x003b1;(198-505), or Ad-&#x003b1;(1-200) in T47D cells were performed to investigate the effect of AFX variants on AFX&#x003b1; induction of apoptosis. Because high amounts of adenoviral vector alone induce cell death, control infections were performed using Ad-E, an MOI (10 and 20 PFU/cell) that was equal to total amount of co-infected adenoviral vectors. Co-infection of Ad-&#x003b1; and Ad-E induced 30&#x02013;40&#x00025; more cell death compared to corresponding amounts of Ad-E infection. Co-infection of Ad-&#x003b6;, Ad-&#x003b1;(198-505), or Ad-&#x003b1;(1-200) prevented AFX&#x003b1; induction of cell death (<xref ref-type="fig" rid="pone-0002743-g005">Fig. 5B</xref>), suggesting dominant negative activity of AFX variants. Cellular examination was also performed using double immunofluorescent. HeLa cells expressing nucleic AFX&#x003b1; alone showed apoptotic nuclei, whereas HeLa cells co-expressing AFX&#x003b1; with AFX&#x003b6; or &#x003b1;(198-505) did not show apoptosis. Of note, AFX&#x003b1; was co-localized with AFX&#x003b6; or &#x003b1;(198-505) in nuclear speckles of these cells (<xref ref-type="fig" rid="pone-0002743-g005">Fig. 5C</xref>).</p><p>The mechanism of dominant negative activity of AFX variants was assessed further by examining effects on transcriptional regulation of 3IRS-TATA-Luc, BCL6p-Luc, and CD2p-Luc. Co-transfection of AFX&#x003b1; with equal or increasing amounts of the AFX variants was preformed in the context of these luciferase reporters. Co-transfection with the AFX variants reduced the AFX&#x003b1;-induced transactivation of 3IRS-TATA-Luc and BCL6p-Luc in a dose-dependent manner (<xref ref-type="fig" rid="pone-0002743-g006">Fig. 6A, B</xref>). The reduction by AFX&#x003b6; was comparable to that of &#x003b1;(1-200). However, the AFX variants did not reverse AFX&#x003b1; suppression of CD2p-Luc activity (<xref ref-type="fig" rid="pone-0002743-g006">Fig. 6C</xref>). These results suggest that the inhibition of AFX&#x003b1;-induced apoptosis is mediated through dominant negative activity of AFX variants on AFX&#x003b1; in BCL6 gene expression.</p><fig id="pone-0002743-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002743.g006</object-id><label>Figure 6</label><caption><title>AFX variants exert dominant negative activity on the BCL6 gene promoter.</title><p>(A, B, C) Co-transfection of AFX&#x003b1; with equal or increasing amounts of the AFX variants was performed in the context of the luciferase reporters, 3IRS-TATA-Luc (A), BCL6p-Luc (B) and CD2p-Luc (C). The &#x003b1;(1-200) construct was used as a known dominant negative mutant. Results were averaged from 3 independent experiments and are plotted as means&#x000b1;standard deviations for quadruplicated well. E, Empty; &#x003b1;, AFX&#x003b1;; and &#x003b6;, AFX&#x003b6;.</p></caption><graphic xlink:href="pone.0002743.g006"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>In this report, we identified spliced forms of AFX transcripts in multiple human cancer cell lines. Short aminoterminal AFX proteins (AFXtr1 and AFXtr2) produced by aberrant splicing were not stable, suggesting AFX inactivation by aberrant splicing. However, alternative splicing and translation produced AFX&#x003b6; and &#x003b1;(198-505), respectively. AFX&#x003b6; and &#x003b1;(198-505) lost the ability to transactivate BCL6 or to suppress cyclin D2 gene expression. Although inactive as individual transcription factors, AFX&#x003b6; and &#x003b1;(198-505) exert dominant negative activity on AFX&#x003b1; stimulation of BCL6 gene. These variants also lost the ability to induce apoptosis but they inhibited AFX&#x003b1; induced apoptosis, presumably through dominant negative activity on the BCL6 gene. Inactivation of AFX by aberrant splicing and the dominant negative function of the AFX splicing variants could therefore provide a growth advantage during cancer progression.</p><p>It has been suggested that AFX&#x003b1; and AFX&#x003b6; may antagonized each other because of their distinct transcriptional activity for different target genes. For example, AFX&#x003b6; stimulates PEPCK, G6Pase promoters, whereas AFX&#x003b1; does not activate these promoters <xref ref-type="bibr" rid="pone.0002743-Yang1">&#x0005b;7&#x0005d;</xref>. We also observed distinct transcriptional regulatory function for AFX&#x003b1; and AFX&#x003b6;. The CD2 promoter was weakly stimulated by AFX&#x003b6; and repressed by AFX&#x003b1; (<xref ref-type="fig" rid="pone-0002743-g004">Fig. 4C</xref>). A novel finding in this study is the dominant negative function of AFX&#x003b6; or &#x003b1;(198-505) on AFX&#x003b1; regulation of the BCL6 promoter. A number of AFX&#x003b1; binding sites have been demonstrated in BCL6 promoter <xref ref-type="bibr" rid="pone.0002743-Tang1">&#x0005b;13&#x0005d;</xref>. One AFX&#x003b1; binding site was also competed by a known forkhead-binding site (IRS) derived from the IGFBP-1 promoter <xref ref-type="bibr" rid="pone.0002743-Tang1">&#x0005b;13&#x0005d;</xref>. Consistent with this, we also observed dominant negative activity by the AFX variants on AFX&#x003b1; stimulation of 3xIRS promoter construct. These results indicate that the dominant negative activity by AFX variants may be mediated through IRS (<named-content content-type="gene">G<underline>CAAAACAA</underline> AC <underline>TTATTTTG</underline>AA</named-content>).</p><p>The induction of BCL6 accounts for part of the apoptotic mechanism mediated by AFX&#x003b1;. FOXO dependent expression of IGFBP-1 <xref ref-type="bibr" rid="pone.0002743-Gan1">&#x0005b;17&#x0005d;</xref>, FasL <xref ref-type="bibr" rid="pone.0002743-Ciechomska1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Barthelemy1">&#x0005b;19&#x0005d;</xref> and Bim <xref ref-type="bibr" rid="pone.0002743-Stahl1">&#x0005b;20&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002743-Urbich1">&#x0005b;23&#x0005d;</xref> have also been shown to promote apoptosis. Direct FOXO binding activity has been demonstrated in the FasL promoter (<named-content content-type="gene">GTAAATAAATA</named-content>) and the Bim promoter (<named-content content-type="gene">GTAAACAC</named-content>). It is possible that the AFX variants may also influence AFX&#x003b1; activation of these genes.</p><p>Of note, the AFX variants did not reverse AFX&#x003b1; suppression of the CD2 promoter. FOXO factors have been shown to elevate p27KIP1 expression and induce cell cycle arrest <xref ref-type="bibr" rid="pone.0002743-Medema1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Nakamura1">&#x0005b;25&#x0005d;</xref>. FOXO3a and AFX have also been shown to inhibit the cell cycle through downregulation of cyclin D by a p27KIP1-independent mechanism <xref ref-type="bibr" rid="pone.0002743-Accili1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Schmidt1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-FernandezdeMattos1">&#x0005b;26&#x0005d;</xref>. Chromatin immunopreciptation (ChIP) using the cyclin D1 <xref ref-type="bibr" rid="pone.0002743-Ramaswamy1">&#x0005b;27&#x0005d;</xref> and cyclin D2 promoters <xref ref-type="bibr" rid="pone.0002743-Park1">&#x0005b;28&#x0005d;</xref> demonstrated FOXO binding on the cyclin D promoters. However, a recent study suggested that transcriptional repression of D-type cyclin may not involve direct binding of FOXO factors to cyclin D1 or D2 promoters <xref ref-type="bibr" rid="pone.0002743-FernandezdeMattos1">&#x0005b;26&#x0005d;</xref>. These results suggest that transcription repressors activated by AFX&#x003b1; might play a role in downregulation of cyclin D.</p><p>An important question is whether there is a causal relationship between AFX splicing variants and cancer. For this to be feasible, the alternative splicing products would need to be expressed at significant levels compared with the normally spliced product <xref ref-type="bibr" rid="pone.0002743-Venables1">&#x0005b;29&#x0005d;</xref>. We compared the pattern of AFX transcripts in two different cell lines (HEK 293 and 293FT) originated from same cells. By RT-PCR there was a decrease of the AFX&#x003b1; transcript in 293FT cells, whereas HEK293 cells still possessed it (<xref ref-type="fig" rid="pone-0002743-g001">Fig. 1A</xref>). HEK293 cells are transformed by the adenovirus E1 gene and 293FT cells were additionally transformed by simian virus (SV) 40 large tumor antigen. Loss of the AFX&#x003b1; transcript and the appearance of the AFX variants could contribute to the higher proliferation of 293FT cells relative to HEK293 cells (data not shown). However, the mechanism described in our study remains to be determined in primary tumors.</p><p>Defects in mRNA splicing occur frequently in human cancer cells <xref ref-type="bibr" rid="pone.0002743-Venables1">&#x0005b;29&#x0005d;</xref> but the mechanisms leading to splicing defects in cancer are poorly understood. A point mutation in the genomic splice site or regulatory elements have been shown in selected splicing defects <xref ref-type="bibr" rid="pone.0002743-Liu1">&#x0005b;30&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002743-Faustino1">&#x0005b;32&#x0005d;</xref>. However, DNA sequencing of the intronic and exonic portions of AFX gene did not reveal mutations. Variations in the composition, concentration, localization, and activity of transacting regulatory factors may also modulate splice-site recognition and usage <xref ref-type="bibr" rid="pone.0002743-Smith1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Caceres1">&#x0005b;34&#x0005d;</xref>. Activation of the oncogenic signal pathway also stimulates aberrant splicing <xref ref-type="bibr" rid="pone.0002743-Matter1">&#x0005b;35&#x0005d;</xref>. It is of interest to better understand how splicing regulatory factors in cancer cells might affect AFX aberrant splicing and thereby cell survival.</p></sec><sec sec-type="methods" id="s4"><title>Methods</title><sec id="s4a"><title>Cells and culture</title><p>Cell lines for ovarian cancer (DOV13, OVCA420, OVCA429, and OVCA433), colon cancer (DLD1, CaCO2), breast cancer (MCF7, T47D), choriocarcinoma (JEG3), hepatoma (HepG2), cervical cancer (HeLa), and transformed human embryonic kidney cells (HEK293, and 293FT) were cultured in DMEM/F12 supplemented with 10&#x00025; fetal bovine serum (FBS), 100 units/ml penicillin, and 100 &#x003bc;g/ml streptomycin. All cells were maintained at 37&#x000b0;C with 5&#x00025; CO2.</p></sec><sec id="s4b"><title>RT-PCR and sequence analysis</title><p>Total RNA was extracted from each cells using TRIZOL reagent (Invitrogen, Carlsbad, CA) as described by the manufacturer. RNA (20 &#x003bc;g) was treated with DNAse-I (Promega, Madison, WI) for 30 min at room temperature. Random hexamers and AMV reverse transcriptase (RT) were used to synthesize cDNA using 10 &#x003bc;g of DNAse-I treated RNA. A portion (1/40) of the cDNA solution was used for amplification of AFX. Cycle conditions were: 2 min hot start at 96&#x000b0;C, followed by 35 cycles of 1 min at 94&#x000b0;C, 45 sec at 56&#x000b0;C, followed by 1 min at 72&#x000b0;C, and a final extension at 72&#x000b0;C for 5 minutes. An aliquot (50&#x00025;) of each PCR reaction was resolved by electrophoresis on 1.8&#x00025; agarose gels and DNA products were visualized with ethidium bromide. Oligonucleotides used for PCR amplification include forward <named-content content-type="gene">5&#x02032;-ACG TAT GGA TCC GGG GAA TG-3&#x02032;</named-content> and reverse <named-content content-type="gene">5&#x02032;-TCC ATC CTG CTG AGC TGT-3&#x02032;</named-content>. PCR product give two bands; AFX&#x003b1; (445 bp) and AFX&#x003b6; (290 bp). The lower AFX&#x003b6; bands were excised and cloned into p-TOPO vector (Invitrogen). To identify splicing variants, 20 positive clones carrying the PCR segment from each cell line were sequenced using an automated DNA sequencer.</p></sec><sec id="s4c"><title>Plasmids and transfections</title><p>The cDNAs for AFX&#x003b1;, AFX&#x003b6;, AFX&#x003b1;(198-505), AFX&#x003b1;(1-200), AFXtr1, and AFXtr2 were amplified using KOD DNA polymerase (Novagen, San Diego CA) and the RT product of total RNAs from cancer cells and cloned into pCR&#x000ae;-Blunt (Invitrogen). After verification of sequencing, each cDNA was subcloned into pCDNA3. Fusion constructs were created by incorporating an N- or C-terminal influenza virus HA epitope (<named-content content-type="gene">YPYDVPDYA</named-content>) in-frame with the AFXs in the pCDNA3 vectors.</p><p>In a preliminary transfection study using the pGL3 basic vector (Promega, Madision WI), we observed that AFX&#x003b1; stimulated luciferase activity about 60-fold. We found 2 IRS-A (<named-content content-type="gene">CAAAACAA</named-content>) sequences in the synthetic polyA (spA) region and removed them (NotI and KpnI). After confirmation that neither AFX&#x003b1; or AFX&#x003b6; stimulated spA deleted pGL3basic vector, the sequences containing 3&#x000d7;insulin response sequences (IRSs, <named-content content-type="gene">G<bold><underline>CAAAACAA</underline></bold> AC <bold><underline>TTATTTTG</underline></bold>AA</named-content>) <xref ref-type="bibr" rid="pone.0002743-Guo1">&#x0005b;36&#x0005d;</xref> and TATA box, the human BCL6 promoter (&#x02212;785 &#x0002b;55) <xref ref-type="bibr" rid="pone.0002743-Tang1">&#x0005b;13&#x0005d;</xref>, and the human cyclin D2 promoter (1302 bps) <xref ref-type="bibr" rid="pone.0002743-Schmidt1">&#x0005b;14&#x0005d;</xref> were inserted into multiple cloning sites to generate 3IRS-TATA-Luc, BCL6p-Luc, and CD2p-luc, respectively.</p><p>Transfections of 293FT cells with 500 ng of luciferase constructs and 10 ng of each AFX construct were performed using the calcium phosphate method. Forty eight hrs later, cells were harvested 48h later and luciferase activity was assayed and normalized as described before <xref ref-type="bibr" rid="pone.0002743-Ishikawa1">&#x0005b;12&#x0005d;</xref>. Results were averaged from 3 independent experiments and are plotted as means&#x000b1;standard deviations for quadruplicated wells.</p></sec><sec id="s4d"><title>Adenoviral infection and cell proliferation assay</title><p>Recombinant adenoviral vectors {Ad-&#x003b1;, Ad-&#x003b1;HA, Ad-&#x003b6;, Ad-&#x003b6;HA, Ad-&#x003b1;(198-505), Ad-&#x003b1;(198-505)HA, and Ad-&#x003b1;(1-200)} carrying each of the AFX cDNAs, with or without HA epitope, were amplified, purified, titrated as described previously <xref ref-type="bibr" rid="pone.0002743-Lee1">&#x0005b;37&#x0005d;</xref>. Cytotoxicity was assessed using a nonradioactive cell proliferation assay according to the manufacturer's protocol (Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega). The day after plating 3&#x000d7;10<sup>3</sup> cells per well in 96-well plates, adenoviral vectors {Ad-&#x003b1;, Ad-&#x003b6;, and Ad-&#x003b1;(198-505)} were infected at various MOIs (2.5-10 plaque forming unit/cell). Empty adenoviral vector (Ad-E) was also infected as a control. To achieve 100&#x00025; cellular expression of adenoviral transgene, MOIs for each cell line were determined by infection of an adenovirus carrying &#x003b2;-galactosidase <xref ref-type="bibr" rid="pone.0002743-Lee1">&#x0005b;37&#x0005d;</xref>. Fresh medium (DMEM/F12 supplemented with 2.5&#x00025; heat inactivated FBS) was added 8 h after infection and every 2 days thereafter. Cell viability was assayed 6 days after infection. Percent cell survival was quantitated relative to Ad-E infected or uninfected cells.</p></sec><sec id="s4e"><title>Immunofluorescence</title><p>Transfected or infected cells were reseeded on cover glasses precoated with fibronectin. Twenty four hrs later, cells were fixed in cold methanol for 10 min and permeabilized in 0.4&#x00025; Triton-X/PBS for 10 min. After washing with TBS/0.05&#x00025; Tween, rat monoclonal anti-HA high affinity antibody (Clone 3F10, 2.5 &#x003bc;g/ml, Roche Diagnostic Co, Manm, Germany) was incubated for 2 hrs. Visualization was performed using anti-rat Ig-biotin, F(ab')2 fragment (5 &#x003bc;g/ml, Jackson Immunoresearch, city) and streptavidin-Texas Red (1&#x02236;100, Vector Laboratories Inc., Burlingame, CA). Cell images were analyzed using a Zeiss microscope (Axioskop, Carl Zeiss Inc., Oberkochen, Germany). For N-terminal specific antibody against AFX (Goat, AFX-N, Santa Cruz Biotechnology, Inc. Santa Cruz CA), biotinylated anti-goat antibody (1&#x02236;300, Vector lab) was used. Each antibody was optimized and titrated to minimize nonspecific activity.</p></sec><sec id="s4f"><title>Immunoprecipitation and Western blot analysis</title><p>Immunoprecipitation and Western blot analysis using lysates from cells were performed as described previously <xref ref-type="bibr" rid="pone.0002743-Nakae2">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002743-Lee2">&#x0005b;38&#x0005d;</xref>. Primary antibodies used were anti-HA high affinity antibody (Roche), anti-AFX antibody (C-terminal specific, A-8975, Sigma- Aldrich, Inc. Saint Louis MO), anti-BCL6 (N-3, Santa Cruz Biotechnology) and anti-cyclin D2 (M-20, Santa Cruz Biotechnology).</p></sec></sec></body><back><ack><p>We thank Tom Kotlar and Wenxia Gu for automated DNA sequencing, Kevin Kordi and Min Ho Lee for the assistance of the cloning.</p></ack><ref-list><title>References</title><ref id="pone.0002743-Arden1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arden</surname><given-names>KC</given-names></name></person-group><year>2004</year><article-title>FoxO: linking new signaling pathways.</article-title><source>Mol Cell</source><volume>14</volume><fpage>416</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">15149589</pub-id></citation></ref><ref id="pone.0002743-Accili1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Accili</surname><given-names>D</given-names></name><name><surname>Arden</surname><given-names>KC</given-names></name></person-group><year>2004</year><article-title>FoxOs at the crossroads of cellular metabolism, differentiation, and transformation.</article-title><source>Cell</source><volume>117</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">15137936</pub-id></citation></ref><ref id="pone.0002743-Burgering1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burgering</surname><given-names>BMT</given-names></name><name><surname>Kops</surname><given-names>GJPL</given-names></name></person-group><year>2002</year><article-title>Cell cycle and death control: long live Forkheads.</article-title><source>Trends in Biochemical Sciences</source><volume>27</volume><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">12114024</pub-id></citation></ref><ref id="pone.0002743-Barr1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>FG</given-names></name></person-group><year>2001</year><article-title>Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.</article-title><source>Oncogene</source><volume>20</volume><fpage>5736</fpage><lpage>5746</lpage><pub-id pub-id-type="pmid">11607823</pub-id></citation></ref><ref id="pone.0002743-So1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>CW</given-names></name><name><surname>Cleary</surname><given-names>ML</given-names></name></person-group><year>2003</year><article-title>Common mechanism for oncogenic activation of MLL by forkhead family proteins.</article-title><source>Blood</source><volume>101</volume><fpage>633</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">12393557</pub-id></citation></ref><ref id="pone.0002743-Scheidler1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheidler</surname><given-names>S</given-names></name><name><surname>Fredericks</surname><given-names>WJ</given-names></name><name><surname>Rauscher</surname><given-names>FJ</given-names><suffix>3rd</suffix></name><name><surname>Barr</surname><given-names>FG</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><year>1996</year><article-title>The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.</article-title><source>Proc Natl Acad Sci U S A</source><volume>93</volume><fpage>9805</fpage><lpage>9809</lpage><pub-id pub-id-type="pmid">8790412</pub-id></citation></ref><ref id="pone.0002743-Yang1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Whelan</surname><given-names>J</given-names></name><name><surname>Babb</surname><given-names>R</given-names></name><name><surname>Bowen</surname><given-names>BR</given-names></name></person-group><year>2002</year><article-title>An mRNA splice variant of the AFX gene with altered transcriptional activity.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>8068</fpage><lpage>8075</lpage><pub-id pub-id-type="pmid">11779849</pub-id></citation></ref><ref id="pone.0002743-VanDerHeide1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Der Heide</surname><given-names>LP</given-names></name><name><surname>Hoekman</surname><given-names>MF</given-names></name><name><surname>Smidt</surname><given-names>MP</given-names></name></person-group><year>2004</year><article-title>The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation.</article-title><source>Biochem J</source><volume>380</volume><fpage>297</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">15005655</pub-id></citation></ref><ref id="pone.0002743-Obsilova1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obsilova</surname><given-names>V</given-names></name><name><surname>Vecer</surname><given-names>J</given-names></name><name><surname>Herman</surname><given-names>P</given-names></name><name><surname>Pabianova</surname><given-names>A</given-names></name><name><surname>Sulc</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>14-3-3 Protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4.</article-title><source>Biochemistry</source><volume>44</volume><fpage>11608</fpage><lpage>11617</lpage><pub-id pub-id-type="pmid">16114898</pub-id></citation></ref><ref id="pone.0002743-Matsuzaki1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>H</given-names></name><name><surname>Ichino</surname><given-names>A</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Kikkawa</surname><given-names>U</given-names></name></person-group><year>2005</year><article-title>Regulation of intracellular localization and transcriptional activity of FOXO4 by protein kinase B through phosphorylation at the motif sites conserved among the FOXO family.</article-title><source>J Biochem (Tokyo)</source><volume>138</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">16272144</pub-id></citation></ref><ref id="pone.0002743-Boura1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boura</surname><given-names>E</given-names></name><name><surname>Silhan</surname><given-names>J</given-names></name><name><surname>Herman</surname><given-names>P</given-names></name><name><surname>Vecer</surname><given-names>J</given-names></name><name><surname>Sulc</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Both the N-terminal loop and wing W2 of the forkhead domain of transcription factor Foxo4 are important for DNA binding.</article-title><source>J Biol Chem</source><volume>282</volume><fpage>8265</fpage><lpage>8275</lpage><pub-id pub-id-type="pmid">17244620</pub-id></citation></ref><ref id="pone.0002743-Ishikawa1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group><year>2004</year><article-title>Nonhomologous end-joining ligation transfers DNA regulatory elements between cointroduced plasmids.</article-title><source>Mol Cell Biol</source><volume>24</volume><fpage>8323</fpage><lpage>8331</lpage><pub-id pub-id-type="pmid">15367654</pub-id></citation></ref><ref id="pone.0002743-Tang1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>TT</given-names></name><name><surname>Dowbenko</surname><given-names>D</given-names></name><name><surname>Jackson</surname><given-names>A</given-names></name><name><surname>Toney</surname><given-names>L</given-names></name><name><surname>Lewin</surname><given-names>DA</given-names></name><etal/></person-group><year>2002</year><article-title>The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>14255</fpage><lpage>14265</lpage><pub-id pub-id-type="pmid">11777915</pub-id></citation></ref><ref id="pone.0002743-Schmidt1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Fernandez de Mattos</surname><given-names>S</given-names></name><name><surname>van der Horst</surname><given-names>A</given-names></name><name><surname>Klompmaker</surname><given-names>R</given-names></name><name><surname>Kops</surname><given-names>GJ</given-names></name><etal/></person-group><year>2002</year><article-title>Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.</article-title><source>Mol Cell Biol</source><volume>22</volume><fpage>7842</fpage><lpage>7852</lpage><pub-id pub-id-type="pmid">12391153</pub-id></citation></ref><ref id="pone.0002743-Nakae1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakae</surname><given-names>J</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Silver</surname><given-names>DL</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name></person-group><year>2001</year><article-title>The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression.</article-title><source>J Clin Invest</source><volume>108</volume><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">11696581</pub-id></citation></ref><ref id="pone.0002743-Nakae2"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakae</surname><given-names>J</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Biggs</surname><given-names>WH</given-names><suffix>3rd</suffix></name><name><surname>Arden</surname><given-names>KC</given-names></name><etal/></person-group><year>2003</year><article-title>The forkhead transcription factor Foxo1 regulates adipocyte differentiation.</article-title><source>Dev Cell</source><volume>4</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">12530968</pub-id></citation></ref><ref id="pone.0002743-Gan1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Bastianetto</surname><given-names>S</given-names></name><name><surname>Dumont</surname><given-names>Y</given-names></name><name><surname>Unterman</surname><given-names>TG</given-names></name><etal/></person-group><year>2005</year><article-title>FoxO-dependent and -independent mechanisms mediate SirT1 effects on IGFBP-1 gene expression.</article-title><source>Biochem Biophys Res Commun</source><volume>337</volume><fpage>1092</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">16236254</pub-id></citation></ref><ref id="pone.0002743-Ciechomska1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechomska</surname><given-names>I</given-names></name><name><surname>Pyrzynska</surname><given-names>B</given-names></name><name><surname>Kazmierczak</surname><given-names>P</given-names></name><name><surname>Kaminska</surname><given-names>B</given-names></name></person-group><year>2003</year><article-title>Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells.</article-title><source>Oncogene</source><volume>22</volume><fpage>7617</fpage><lpage>7627</lpage><pub-id pub-id-type="pmid">14576824</pub-id></citation></ref><ref id="pone.0002743-Barthelemy1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barthelemy</surname><given-names>C</given-names></name><name><surname>Henderson</surname><given-names>CE</given-names></name><name><surname>Pettmann</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK.</article-title><source>BMC Neurosci</source><volume>5</volume><fpage>48</fpage><pub-id pub-id-type="pmid">15569384</pub-id></citation></ref><ref id="pone.0002743-Stahl1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Dijkers</surname><given-names>PF</given-names></name><name><surname>Kops</surname><given-names>GJ</given-names></name><name><surname>Lens</surname><given-names>SM</given-names></name><name><surname>Coffer</surname><given-names>PJ</given-names></name><etal/></person-group><year>2002</year><article-title>The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2.</article-title><source>J Immunol</source><volume>168</volume><fpage>5024</fpage><lpage>5031</lpage><pub-id pub-id-type="pmid">11994454</pub-id></citation></ref><ref id="pone.0002743-Gilley1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilley</surname><given-names>J</given-names></name><name><surname>Coffer</surname><given-names>PJ</given-names></name><name><surname>Ham</surname><given-names>J</given-names></name></person-group><year>2003</year><article-title>FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons.</article-title><source>J Cell Biol</source><volume>162</volume><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">12913110</pub-id></citation></ref><ref id="pone.0002743-Sunters1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sunters</surname><given-names>A</given-names></name><name><surname>Fernandez de Mattos</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Brosens</surname><given-names>JJ</given-names></name><name><surname>Zoumpoulidou</surname><given-names>G</given-names></name><etal/></person-group><year>2003</year><article-title>FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>49795</fpage><lpage>49805</lpage><pub-id pub-id-type="pmid">14527951</pub-id></citation></ref><ref id="pone.0002743-Urbich1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urbich</surname><given-names>C</given-names></name><name><surname>Knau</surname><given-names>A</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>DH</given-names></name><name><surname>Bruhl</surname><given-names>T</given-names></name><etal/></person-group><year>2005</year><article-title>FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells.</article-title><source>Faseb J</source><volume>19</volume><fpage>974</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">15824087</pub-id></citation></ref><ref id="pone.0002743-Medema1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>RH</given-names></name><name><surname>Kops</surname><given-names>GJ</given-names></name><name><surname>Bos</surname><given-names>JL</given-names></name><name><surname>Burgering</surname><given-names>BM</given-names></name></person-group><year>2000</year><article-title>AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1.</article-title><source>Nature</source><volume>404</volume><fpage>782</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">10783894</pub-id></citation></ref><ref id="pone.0002743-Nakamura1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.</article-title><source>Mol Cell Biol</source><volume>20</volume><fpage>8969</fpage><lpage>8982</lpage><pub-id pub-id-type="pmid">11073996</pub-id></citation></ref><ref id="pone.0002743-FernandezdeMattos1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez de Mattos</surname><given-names>S</given-names></name><name><surname>Essafi</surname><given-names>A</given-names></name><name><surname>Soeiro</surname><given-names>I</given-names></name><name><surname>Pietersen</surname><given-names>AM</given-names></name><name><surname>Birkenkamp</surname><given-names>KU</given-names></name><etal/></person-group><year>2004</year><article-title>FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.</article-title><source>Mol Cell Biol</source><volume>24</volume><fpage>10058</fpage><lpage>10071</lpage><pub-id pub-id-type="pmid">15509806</pub-id></citation></ref><ref id="pone.0002743-Ramaswamy1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><name><surname>Sansal</surname><given-names>I</given-names></name><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><year>2002</year><article-title>A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR.</article-title><source>Cancer Cell</source><volume>2</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12150827</pub-id></citation></ref><ref id="pone.0002743-Park1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Maizels</surname><given-names>ET</given-names></name><name><surname>Feiger</surname><given-names>ZJ</given-names></name><name><surname>Alam</surname><given-names>H</given-names></name><name><surname>Peters</surname><given-names>CA</given-names></name><etal/></person-group><year>2005</year><article-title>Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>9135</fpage><lpage>9148</lpage><pub-id pub-id-type="pmid">15613482</pub-id></citation></ref><ref id="pone.0002743-Venables1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venables</surname><given-names>JP</given-names></name></person-group><year>2004</year><article-title>Aberrant and alternative splicing in cancer.</article-title><source>Cancer Res</source><volume>64</volume><fpage>7647</fpage><lpage>7654</lpage><pub-id pub-id-type="pmid">15520162</pub-id></citation></ref><ref id="pone.0002743-Liu1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HX</given-names></name><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>MQ</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><year>2001</year><article-title>A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes.</article-title><source>Nat Genet</source><volume>27</volume><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11137998</pub-id></citation></ref><ref id="pone.0002743-Cartegni1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Chew</surname><given-names>SL</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><year>2002</year><article-title>Listening to silence and understanding nonsense: exonic mutations that affect splicing.</article-title><source>Nat Rev Genet</source><volume>3</volume><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">11967553</pub-id></citation></ref><ref id="pone.0002743-Faustino1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faustino</surname><given-names>NA</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name></person-group><year>2003</year><article-title>Pre-mRNA splicing and human disease.</article-title><source>Genes Dev</source><volume>17</volume><fpage>419</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">12600935</pub-id></citation></ref><ref id="pone.0002743-Smith1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PJ</given-names></name><name><surname>Spurrell</surname><given-names>EL</given-names></name><name><surname>Coakley</surname><given-names>J</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name><name><surname>Ross</surname><given-names>RJ</given-names></name><etal/></person-group><year>2002</year><article-title>An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor.</article-title><source>Endocrinology</source><volume>143</volume><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">11751603</pub-id></citation></ref><ref id="pone.0002743-Caceres1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caceres</surname><given-names>JF</given-names></name><name><surname>Kornblihtt</surname><given-names>AR</given-names></name></person-group><year>2002</year><article-title>Alternative splicing: multiple control mechanisms and involvement in human disease.</article-title><source>Trends Genet</source><volume>18</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">11932019</pub-id></citation></ref><ref id="pone.0002743-Matter1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matter</surname><given-names>N</given-names></name><name><surname>Herrlich</surname><given-names>P</given-names></name><name><surname>Konig</surname><given-names>H</given-names></name></person-group><year>2002</year><article-title>Signal-dependent regulation of splicing via phosphorylation of Sam68.</article-title><source>Nature</source><volume>420</volume><fpage>691</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">12478298</pub-id></citation></ref><ref id="pone.0002743-Guo1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Rena</surname><given-names>G</given-names></name><name><surname>Cichy</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><etal/></person-group><year>1999</year><article-title>Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence.</article-title><source>J Biol Chem</source><volume>274</volume><fpage>17184</fpage><lpage>17192</lpage><pub-id pub-id-type="pmid">10358076</pub-id></citation></ref><ref id="pone.0002743-Lee1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Anderson</surname><given-names>LM</given-names></name><name><surname>Thimmapaya</surname><given-names>B</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group><year>1999</year><article-title>Targeted expression of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors.</article-title><source>J Clin Endocrinol Metab</source><volume>84</volume><fpage>786</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">10022454</pub-id></citation></ref><ref id="pone.0002743-Lee2"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Jakacka</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>WR</given-names></name><name><surname>Chien</surname><given-names>PY</given-names></name><name><surname>Martinson</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice.</article-title><source>Mol Med</source><volume>7</volume><fpage>773</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">11788792</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>CMB-YUHAN Research Grant from Yonsei University College of Medicine (2007-01). The sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 